From data acquired thus far, we hypothesise that CXCL8 is involved in promoting a stroma‐rich microenvironment which aids tumour immune evasion and EMT, and that targeting this pathway could be therapeutically beneficial in a subset of patients with right‐sided tumours. Here, CXCL8 is linked to neoplasm.